Immuron is on track to exceed A$7 million in sales this financial year, which is a momentous increase on the previous year's sales of A$4.9 million.
1 month ago

The company is set to exceed A$7 million in sales for the current financial year, marking a substantial increase from A$4.9 million in the previous year.
1 month ago

Immuron hosts a proprietary technology platform that develops specific oral antibodies to address urgent medical needs. · Immuron is a publicly...
5 months ago

Immuron Limited ( ($AU:IMC) ) has shared an announcement. Immuron Limited has announced a change in the substantial holding of its shares by The Bank of New...
1 week ago

ProIBS^® is a certified medical device for the treatment of IBS symptoms such as abdominal pain, bloating and unsettled bowel movements (...
4 months ago

Immuron reports record Travelan sales ... Immuron Ltd (NASDAQ:IMRN), a biopharmaceutical company, has announced its highest ever sales for its...
3 months ago

The company ranks as one of the best Australian stocks to buy according to analysts. Overall, IMRN ranks 4th on our list of best Australian stocks to buy...
1 month ago

Immuron Letter to Shareholders: Projects Update | IMRN Stock News · Immuron (IMRN, Financial) projects over A$7 million in sales for the current...
1 month ago

Immuron has exceeded A$5 million in sales - our highest fiscal year sales ever! That is with a quarter to come. This is a fantastic result.
3 months ago

The aim of the collaboration is to develop an enhanced formulation of Travelan for military use against pathogens that cause diarrhoea,...
10 months ago